Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study

12 Mar 2024

Abstract excerpt

Real-world data have revealed that a substantial portion of patients with myelodysplastic syndromes (MDS) does not respond to epigenetic therapy with hypomethylating agents (HMAs). The cellular and molecular reasons for this resistance to the demethylating agent and biomarkers that would be able to predict the treatment refractoriness are largely unknown. In this study, we shed light on this enigma by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38471524
DOI: 10.1111/bjh.19392

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studyPMID 38471524Read ↗

Unique epigenomic signatures identify biologically significant subtypes of MDS and predict response to azacitidineSemantic proximity Read ↗

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survivalSemantic proximity Read ↗

The epigenomics revolution in myelodysplasia: a clinico-pathological perspective.Semantic proximity Read ↗

Azacytidine causes complex DNA methylation responses in myeloid leukemiaSemantic proximity Read ↗

The DNA methylation landscape of hematological malignancies: an updateSemantic proximity Read ↗

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related diseaseSemantic proximity Read ↗

Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic ToolSemantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Single cell multiomics reveal clonal and functional dynamics of MDS stem/progenitor cells during hypomethylating therapySemantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic SyndromesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.